In platelets, group IVA cytosolic phospholipase A 2 (cPLA 2 a) has been implicated as a key regulator in the hydrolysis of platelet membrane phospholipids, leading to pro-thrombotic thromboxane A 2 and anti-thrombotic 12-(S)-hydroxyeicosatetranoic acid production. However, studies using cPLA 2 a-deficient mice have indicated that other PLA 2 (s) may also be involved in the hydrolysis of platelet glycerophospholipids. In this study, we found that group VIB Ca 2+ -independent PLA 2 (iPLA 2 c)-deficient platelets showed decreases in adenosine diphosphate (ADP)-dependent aggregation and ADP-or collagen-dependent thromboxane A 2 production. Electrospray ionization mass spectrometry analysis of platelet phospholipids revealed that fatty acyl compositions of ethanolamine plasmalogen and phosphatidylglycerol were altered in platelets from iPLA 2 c-null mice. Furthermore, mice lacking iPLA 2 c displayed prolonged bleeding times and were protected against pulmonary thromboembolism. These results suggest that iPLA 2 c is an additional, long-sought-after PLA 2 that hydrolyzes platelet membranes and facilitates platelet aggregation in response to ADP.
Introduction
Platelets play a key role in hemostasis through their ability to respond to vascular injury. When circulating platelets are exposed to collagen-rich subendothelium at the site of a vascular injury, platelets become activated, release granule contents, and generate thrombin and the lipid mediator thromboxane A 2 (TXA 2 ) [1, 2] . Secreted adenosine diphosphate (ADP), serotonin, and TXA 2 amplify the initial stimulus in a positive feedback activation of platelets. In addition, a-granule proteins, such as P-selectin, which mediate adhesive interactions between platelets, leukocytes, and endothelial cells, play a pivotal role in the pathogenesis of thrombosis and inflammation [2, 3] . TXA 2 is a potent platelet agonist and an arachidonic acid (AA) metabolite, produced via the cyclooxygenase (COX) pathway [4, 5] . Another platelet-derived lipid mediator, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), is also an AA metabolite produced via platelet-type 12-lipoxygenase and acts as a platelet antagonist [6, 7] . TXA 2 formation is rapid and quickly reaches a plateau in activated platelets, whereas 12(S)-HETE formation is slower and continues to increase over a longer period of time.
AA is released from the sn-2 position of glycerophospholipids by the action of phospholipase A 2 (PLA 2 ). PLA 2 enzymes have been classified into six major families: secretory PLA 2 (sPLA 2 ), cytosolic PLA 2 (cPLA 2 ), Ca 2+ -independent PLA 2 (iPLA 2 ), platelet-activating factor acetylhydrolases, lysosomal PLA 2 s and adipose-specific PLA 2 ; each family occurs as multiple isoforms [8] . Platelets are known to contain both cPLA 2 a (also known as group IVA PLA 2 ), a cPLA 2 enzyme that requires micromolar concentrations of intracellular Ca 2+ for translocation to membrane phospholipids, and group IIA sPLA 2 (sPLA 2 -IIA), an sPLA 2 enzyme that requires millimolar Ca 2+ concentrations for its enzymatic activity [8] . AA production in platelets is dependent on cPLA 2 a but not on sPLA 2 -IIA [9] . A functional deficiency of cPLA 2 a diminished platelet aggregatory and secretory responses to collagen [10] . cPLA 2 adeficient mice have prolonged bleeding times and are resistant to thromboembolism induced by injection of a mixture of ADP and collagen, indicating a role of this enzyme in platelet adhesive and hemostatic functions. However, residual AA release and TXA 2 production were still observed in collagen-or ADP-stimulated platelets isolated from cPLA 2 a/sPLA 2 -IIA double-deficient mice. Furthermore, bromoenol lactone (BEL), an iPLA 2 inhibitor, inhibits AA production in 12-O-tetradecanoylphorbol-13-acetate (PMA)-or thrombin-stimulated platelets [11, 12] . These reports have suggested that another PLA 2 enzyme, possibly BEL-sensitive iPLA 2 enzyme(s), may compensate for platelet activation.
To date, nine members of the iPLA 2 family, also referred to as the patatin-like phospholipase-domain containing (PNPLA) family, have been identified. These iPLA 2 isoforms have one or more nucleotide-binding motif (GXGXXG) and a lipase consensus site (GXSXG) separated by a 10-40-amino acid residue spacer linkage [13, 14] . Unlike cPLA 2 s and sPLA 2 s, iPLA 2 s do not require intracellular Ca 2+ for enzymatic activity or membrane binding, and they are sensitive to BEL [15] [16] [17] . Among iPLA 2 s, it is assumed that two abundant isoforms -iPLA 2 c/PNPLA8 (group VIB) and iPLA 2 b/PNPLA9 (group VIA)-serve as housekeeping enzymes responsible for phospholipid acyl group turnover and generation of the lysophospholipids necessary for AA incorporation [14, 18, 19] .
Recently, several studies have revealed the role of iPLA 2 c in lipid mediator production. For example, overexpression of iPLA 2 c has been shown to promote spontaneous and agonist-stimulated release of AA, which is converted to prostaglandin E 2 (PGE 2 ) with preferred COX-1 coupling in HEK293 cells [20] . The induction of group IIA sPLA 2 by pro-inflammatory stimuli has been shown to require iPLA 2 c through production of certain lipid metabolite(s) in rat fibroblastic 3Y1 cells [21] . iPLA 2 c could produce 2-arachidonoyl-lysophosphatidylcholine, a presumptive lipid mediator, through its PLA 1 action [22] . In addition, disruption of the iPLA 2 c gene in mice reduced the levels of prostaglandin F 2a (PGF 2a ) and D 2 (PGD 2 ) in skeletal and heart muscle and those of TXA 2 in heart muscle [23] . Moreover, Ca 2+ -induced myocardial activation of iPLA 2 c and the attendant release of AA and its metabolites, were attenuated by genetic ablation of iPLA 2 c [24] . These results raise the possibility that iPLA 2 c may be involved in AA release from glycerophospholipids in activated platelets.
In the current study, we investigated the role of iPLA 2 c in platelets using iPLA 2 c knockout (iPLA 2 c-KO) mice. Our findings demonstrate that lack of iPLA 2 c expression in vivo increased bleeding time and protected mice from thromboembolism. In studies using isolated platelets, iPLA 2 c-KO mouse platelets were aggregated only poorly, and produced a reduced level of TXA 2 in response to ADP. Furthermore, electrospray ionization mass spectrometry (ESI-MS) analysis of platelet phospholipids suggested that iPLA 2 c mainly catalyzed the hydrolysis of AA-containing plasmalogen-type phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) and subclasses in activated platelets. These results indicate that, together with cPLA 2 a, iPLA 2 c plays a role in AA mobilization from specific AA-containing phosholipid pools in activated platelets.
Materials and Methods

Antibodies and Reagents
The study used iPLA 2 c-KO mice on a C57BL/6j background, as described in a previous study [23] . All procedures involving animals were approved by the Institutional Animal Care and Use Committees of Showa University. ADP, prostaglandin E 1 (PGE 1 ), thrombin and anti-b-actin monoclonal antibody were purchased from Sigma (St Louis, MO). U46619 and AA were from Cayman Chemical (Ann Arbor, Michigan). Collagen reagent Horm (native collagen fibrils from equine tendons) was purchased from Nycomed Arzneimittel (Munchen, Germany). MRS2365 and MRS2279 were purchased from TOCRIS bioscience (Bristol, UK). Phosphatidylcholine (PC) with C 28:0 , PE with C 28:0 and PG with C 28:0 were from Avanti Polar Lipids, Inc. (Alabaster, AL).
Paraformaldehyde, glutaraldehyde, EPON, and uranyl acetate were obtained from TAAB Laboratories (Aldermaston, West Berkshire, UK). Rabbit anti-adenylyl cyclase (AC), phosphodiesterase (PDE) 3A and PDE5 polyclonal antibody, anti-cPLA 2 a monoclonal antibody and goat anti-COX-1 and G ai antibody were purchased from Zymed Laboratories (South San Francisco, CA). Rabbit anti-iPLA 2 c polyclonal antibody was prepared as described in previous studies [21, 23] .
Isolation of Platelets
Mice anesthetized with diethyl ether were used for cardiac puncture. The heart was exposed and a 1-ml syringe with a 25-gauge needle containing 100 ml of 3.8% (w/v) trisodium citrate was used to obtain about 1 ml of blood. The platelet-rich plasma (PRP) was obtained by centrifugation of whole blood at 2506g for 10 min at room temperature, platelet-poor plasma (PPP) was obtained by centrifugation of lower-phase blood at 8006g for 15 
Platelet Aggregation
Platelet aggregation (180 ml samples) was assessed in an aggregometer (HEMA tracer, LMS Co., Ltd., Tokyo, Japan) with constant stirring (100 rpm) at 37uC. The platelets were then incubated with various inhibitors, and without stirring, at 37uC, for various periods of time before agonists were added: collagen (1 mg/ml), ADP (10 mM), U46619 (5 mM), thrombin (0.1 U/ml), A23187 (5 mM), AA (100 mM), PMA (10 nM), MRS2365 (10 mM) and MRS2279 (10 mM). Aggregation was measured and expressed as a percent change in light transmission, with the value for blank sample (PPP or H/T buffer without platelets) set at 100%.
SDS-PAGE and Immunoblotting
Ten-mg protein was subjected to SDS-PAGE using 7.5% or 12% gels under reducing conditions. The separated proteins were electroblotted onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) with a semidry blotter (Bio-Rad Laboratories, Hercules, USA) according to the manufacturer's instructions. After blocking with 5% (w/v) skim milk in 10 mM Tris-HCl, pH 7.4, containing 150 mM NaCl and 0.05% Tween 20, membranes were probed with the respective antibodies (1:5,000 dilution for iPLA 2 c COX-1, P2Y 1 , P2Y 12 , AC, PDE3A, PDE5 and G ai ; 1:10,000 dilution for cPLA 2 a and b-actin) for 1 h, then incubated with horseradish peroxidase-conjugated anti-rabbit (1:5,000 for iPLA 2 c P2Y 1 , P2Y 12 , AC, PDE3A and PDE5) IgG, peroxidase-conjugated anti-goat (1:5,000 for COX-1 and G ai ) IgG and peroxidase-conjugated anti-mouse (1:10,000 for cPLA 2 a and b-actin) IgG. After washing, the membranes were visualized with Western Lightning Chemiluminescence Reagent Plus (Perkin Elmer Life Sciences, Boston, MA, USA).
Reverse Transcription PCR
Total RNA was extracted from mouse platelets with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Firststrand cDNA synthesis was conducted using the SuperScript III reverse transcriptase kit (Invitrogen Life Technologies) according to the manufacture's instructions. Five mg of total RNA in reaction mixture was primed with oligo (dT) (12-18 mer) primer (Invitrogen Life Technologies) to obtain cDNA. Then, 1 ml of the synthesized cDNA was used as the template for the mRNA amplification reactions. The PCR conditions were 96uC for 5 min, then 35 cycles of 96uC and 63uC for 30 s, and finally 68uC for 2 min on a thermal cycler (Applied Biosystetms). The reverse transcription PCR products were analyzed by 1% agarose gel electrophoresis with ethidium bromide. The primer pairs were Pla2g4a (forward: 59-gcatggcactgtgtgatcag-39, reverse: 59-cgtgaagagaggcaaaggaca-39); Pla2g6 (forward: 59-gcaaacactggcactctc- caag-39, reverse: 59-cggagaatgactccaaatctgg-39); Pnpla8 (forward: 59-gagactgccttccattacgct-39, reverse: 59-tcgtttggggtgtccacttc-39).
Electron Microscopy
The platelets suspended in H/T buffer were fixed by mixing with an equal volume of 2% glutaraldehyde in 0.1 M phosphate buffer (PB, pH 7.4) for 30 min at room temperture. The fixed cells were transferred to eppendorf tubes, then centrifuged at 2,000 rpm for 5 min at 4uC. The platelet pellets were dissected into blocks of 1-mm cubes, washed 5 times in 0.1 M PB, post-fixed with 1% osmium tetroxide in the same buffer for 1 h at 4uC, dehydrated with a graded ethanol series, and then embeded in Epon 812, according to the conventional method. Ultra-thin sections were cut with a diamond knife and stained with uranyl acetate and lead citrate, then examined with a JEM-1200EX electron microscope (JEOL, Tokyo, Japan) at an accelerating voltage of 80 kV.
Measurement of ATP and Serotonin Secretion
After the reaction, platelets were removed by centrifugation in the presence of 5 mM of ice cold EDTA and 10 mg/ml indomethacin. The amounts of adenosine triphosphate (ATP) and serotonin in platelet-free supernatant fraction was measured using an ATP bioluminescence assay kit CLS II (Roche Applied Science, Mannheim, Germany) and EIA Serotonin kit (IMMU-NOTECH SAS, Marseille, France), respectively, according to the manufacturer's protocol.
Ca
2+ Influx
Washed platelets were loaded with fura-2 by incubation in RPMI1640 medium containing 5 mM fura-2/AM (Dojindo Laboratories, Kumamoto, Japan), PGE 1 and 10% fetal bovine serum at 37uC for 40 min. The fura-2-loaded platelets were washed with H/T buffer (pH 7.35) containing PGE 1 twice and resuspended in loading solution (145 mM NaCl, 10 mM HEPES, 10 mM MgCl 2 , 6 mM glucose, 5 mM KCl (pH 7.35)) at a 3 /ml, then activated with 10 mM ADP. Fluorescence was continuously recorded using CAF-110 (JASCO Co., Ltd., Tokyo, Japan) at 37uC by alternating the excitation wavelength between 340 and 380 nm, and detecting the fluorescent emission at 510 nm with the bandwidth set at 2.5 nm for both emission and excitation.
Analysis of Intraplatelet cAMP Levels
PRP (200610 3 /ml) was incubated both with and without forskolin (FK) for 30 s before ADP was added and the samples were incubated for 5 min at room temperature. FK stimulates AC and then increase intraplatelet cAMP levels. The reaction was stopped by the addition of 50 ml of ice-cold 30% (v/v) trichloroacetic acid. Samples were mixed and centrifuged at 6,0006g for 20 min at 4uC. Supernatants were removed and retained, and the pH was neutralized by addition of 8 mM KOH. Samples were stored at 280uC and assayed for cAMP using Amersham cAMP Biotrak EIA system (GE healthcare, UK) according to the manufacturer's instructions.
ESI-MS Analysis of Phospholipids
Platelets (3.6610 7 cells) were soaked in 200 ml of H 2 O and then sonicated for 30 s. Lipids were extracted from the lysates using the method described in Bligh and Dyer [25] . Before lipid extraction, nium formate (pH 6.8)) at a flow-rate of 10 ml/min. The scan range of the instrument was set at m/z 400-1000, with a scan speed of 10000 Da/s. The trap fill-time was set at 20 ms in the negative-ion mode. The ion spray voltage was set at 5500 V in the negative-ion mode. Nitrogen was used as curtain gas (setting of 20, arbitrary units) and as collision gas (set to ''high''). The declustering potential was set at 60 V in the negative-ion mode. The collision energy in ESI-MS and ESI-MS/MS analyses were optimized according to the requirements of the experiment.
Mediator Lipidomics
After 10 min of reaction, platelets were removed by centrifugation in the presence of 5 mM of ice cold EDTA and 10 mg/ml indomethacin. The platelet-free supernatant fraction was used for mediator lipidomics. Mediator lipidomics was performed as described previously [26] . Before eicosanoids extraction, 0.1 ng of prostaglandin B 2 (GE Healthcare) was added to each sample as an internal standard. Then, 0.2% (v/v) formic acid and ethyl acetate were added to each sample before centrifugation. Supernatants were removed and used for ESI-MS/MS analysis with a 5500Q-TRAP quadrupole-linear ion trap hybrid mass spectrometer with an Ultimate 3000 HPLC system and TSKgel ODS-100V C18 column (5 mm, 4.66150 mm; Tosoh Bioscience, Tokyo, Japan). Samples were eluted with a mobile phase composed of water/acetonitrile/formic acid (63:37:0.02) and acetonitrile/isoplopanol (50:50) 73:23, for 5 min, ramped to 30:70 after 15 min, ramped to 20:80 after 25 min and held for 8 min, then ramped to 0:100 after 35 min and held for 10 min, with flow rates of 70 ml/min (0-30 min), 80 ml/min (30-33 min), and 100 ml/min (33-45 min). ESI-MS/MS analyses were conducted in negative ion mode, and eicosanoids were indicated and quantified by multiple reaction monitoring (MRM). Calibration curves (1-1000 pg) and LC retention times for each compound were established with synthetic standards.
Bleeding Time Measurement
Bleeding time was assessed according to a previously reported method [10] . In brief, 8,9-wks of age male mice were restrained in the upright position and their tails were transected 5 mm proximal from the tip. The remaining tail was then immersed in saline at 37uC. Bleeding time was defined as either the point at Figure 5 . ESI/MS analysis of plasmalogen-PE and PG species in WT and iPLA 2 c-KO mouse platelets. Total lipids were extracted from resting or ADP (10 mM)-stimulated platelet lysates and then subjected to ESI/MS analysis of PG and PE. Levels of (A) plasmalogen-PE and (B) PG in resting state of WT (-) or iPLA 2 c-KO platelets (-), or ADP-stimulated WT (ADP) or iPLA 2 c-KO platelets (ADP), and collagen (1 mg/ml)-stimulated WT (collagen) or iPLA 2 c-KO platelets (collagen) (n = 7). Results are given as mean6SEM. *P,0.05 between iPLA 2 c-KO and WT. doi:10.1371/journal.pone.0109409.g005 which all visible signs of bleeding from the incision stopped, or at 10 min.
Thromboembolism Test
The tail veins of mice anesthetized with 5 mg/kg sodium pentbarbital were injected with 0.25 mg/kg collagen and 20 mg/ kg of epinephrine dissolved in a buffer. Survival was evaluated 1 h after injection. Statistical analysis between WT and iPLA 2 c-KO groups was assessed by Fisher's exact test. The amount of collagen and epinephrine used was determined as that which induced mortality of 80%-90% in wild-type (WT) mice. For histological examination, mice were killed 2 min after injection, the heart was exposed and a 1-ml syringe with a 25-gauge needle containing EDTA powder was used to obtain about 200 ml of blood. The plasma was obtained by centrifugation of whole blood at 10,0006g for 15 min at 4uC, and the lungs were excised. Tissue preparations were stained with hematoxylin and eosin, and the lungs were homogenate in 1 ml of methanol. Lipids were extracted from the lysates by the method detailed in Bligh and Dyer. The thromboxane B 2 (TXB 2 ) contents of serum or lung were then used for ESI-MS/MS analysis.
Data Analysis
Results are shown as mean6SEM from at least three individual experiments per group. Statistical analyses between WT and iPLA 2 c-KO groups were assessed by student t test. P values less than 0.05 were considered statistically significant.
Results
iPLA 2 c Expression in Murine Platelets and Morphological Features of iPLA 2 c-Deficient Mouse Platelets
We first examined whether mRNAs for iPLA 2 b and iPLA 2 c were expressed in murine platelets using the RT-PCR method ( Figure 1A) . Expression of mRNAs for iPLA 2 c (Pnpla8) and cPLA 2 a (Pla2g4a) was detected, but not for iPLA 2 b (Pla2g6); meanwhile, the two iPLA 2 s and, to a lesser extent, cPLA 2 a were expressed in the heart used as a positive control. The absence of iPLA 2 c protein in the iPLA 2 c-KO mouse platelets was confirmed by western blot analysis of platelet lysates. The protein levels of COX-1 and cPLA 2 a were not significantly different between WT and iPLA 2 c-KO mouse platelets ( Figure 1B ). There were no abnormalities in the platelet numbers and mean platelet volume in iPLA 2 c-KO mice (Table 1) . Furthermore, electron microscopy Figure 6 . ESI/MS analysis of diacyl-type PE and PC species in WT and iPLA 2 c-KO mouse platelets. Total lipids were extracted from resting or ADP (10 mM)-stimulated platelet lysates and then subjected to ESI/MS analysis of diacyl-type PE and PC. Levels of (A) diacyl-type PE and (B) PC in resting state of WT (-) or iPLA 2 c-KO platelets (-), or ADP-stimulated WT (ADP) or iPLA 2 c-KO platelets (ADP), and collagen (1 mg/ml)-stimulated WT (collagen) or iPLA 2 c-KO platelets (collagen) (n = 7). Results are given as mean6SEM. doi:10.1371/journal.pone. 0109409.g006 revealed that resting iPLA 2 c-KO mouse platelets showed a normal discoid morphology ( Figure 1C) . Although previous reports showed that iPLA 2 c-KO mice had abnormal mitochondria in skeletal muscle, myocardium and brain [23, 29] , mitochondrial architecture was virtually normal in iPLA 2 c null mouse platelets. The average length of the major axis of mitochondria in platelets was not significantly affected by iPLA 2 c deficiency ( Figure 1D ).
Reduced ADP-dependent Aggregation of iPLA 2 cdeficient Mouse Platelets
As shown in Figure 2 , functional studies of platelets from iPLA 2 c-KO mice, compared to WT mice, revealed that ADPinduced aggregation was reduced, whereas aggregation in response to other platelet activators, including collagen, thrombin, Ca 2+ -ionophore (A23187), PMA, AA and TXA 2 receptor (TP) agonist (U46619) were similar between iPLA 2 c-KO and WT platelets. Even when PRP was stimulated with ADP, platelet aggregation was also reduced by iPLA 2 c deficiency. The release of the contents in platelet-dense granules has been thought to play an important role in perpetuating the aggregation response [1, 3] . We therefore investigated the effect of iPLA 2 c deletion on ADPinduced dense granule release by quantifying liberated ATP and serotonin. In response to ADP, platelets from iPLA 2 c-KO mouse secreted ATP and serotonin to levels comparable to those from WT platelets ( Figure 3A and B) . Moreover, intracellular ATP levels were not significantly different between WT and iPLA 2 cdeficient mouse platelets ( Figure 3C ). These results indicated that iPLA 2 c deletion affected neither ADP-induced dense granule release nor cellular ATP synthesis, which is consistent with normal mitochondrial morphology in the iPLA 2 c-KO mice ( Figure 1C) .
ADP induces platelet aggregation through two G-protein coupled receptors ---G q -coupled P2Y 1 , and G i -coupled P2Y 12 [28, 29] . The protein levels of P2Y 1 and P2Y 12 in iPLA 2 c-deficient mouse platelets were similar to those in WT platelets ( Figure 3D ). Like ADP-induced platelet aggregation, P2Y 1 agonist MRS2365-induced aggregation was also reduced by iPLA 2 c deficiency ( Figure 3E ). On the other hand, when platelets were pretreated with P2Y 1 antagonist MRS2279 and then stimulated with ADP, platelet aggregation from iPLA 2 c-KO mouse was similar to that of WT platelets ( Figure 3F ). These results indicated that iPLA 2 c is involved in P2Y 1 -mediated platelet aggregation by ADP stimulation, not P2Y 12 -. P2Y 1 receptor stimulation increases intracellular Ca 2+ levels by phospholipase Cb activation, and P2Y 12 receptor stimulation results in G ai -mediated inhibition of AC [28, 29] . We further examined the effects of iPLA 2 c deficiency on ADP-induced second messenger signaling, but our analysis revealed that there was little difference in second messenger signaling between WT and iPLA 2 c-deficient mouse platelets. ADP-induced increment in intracellular Ca 2+ levels was not significantly affected by iPLA 2 c deficiency ( Figure 3G) . Notably, intracellular cAMP levels in nontreated iPLA 2 c-deficient mouse platelet were significantly higher than in WT platelets ( Figure 3H ), although the protein levels of AC, PDE3A, PDE5 and G ai subunit in iPLA 2 c-deficient mouse platelets were similar to those in WT platelets ( Figure 3D) . However, the increased cAMP level in FK-treated iPLA 2 cdeficient mouse platelets was decreased by ADP stimulation to a level similar to that in WT platelets ( Figure 3H ).
Lipidomics of Platelets
We further examined the effects of iPLA 2 c deletion on AA release and production of AA metabolites by ADP-activated platelets using ESI-MS/MS analysis. Release of AA and TXA 2 (measured as its stable analog, TXB 2 ) from iPLA 2 c-deficient mouse platelets was significantly reduced compared to that of WT platelets ( Figure 4A and B) . Although there were no significant differences between genotypes, the levels of other AA metabolites, such as 12(S)-HETE, PGE 2 and PGD 2 also tended to be lower in iPLA 2 c-KO mouse platelets than in WT mouse platelets ( Figure 4B and C) . In addition, collagen-induced TXA 2 generation was decreased in iPLA 2 c-deficient mouse platelets, although TXA 2 generation in response to thrombin, A23187, PMA, AA and U46619 were not significantly different ( Figure 4D) .
To assess the contribution of iPLA 2 c to stimulant-dependent phospholipid hydrolysis in platelets, we performed ESI/MS lipidomics analysis. Interestingly, some specific species of phospholipids, namely alkenyl forms of PE (plasmalogen PE) and PG bearing C 18:2 (linoleic acid) or C 20:4 (AA) at the sn-2 position, were selectively decreased by ADP stimulation in WT platelets, whereas the decrease of these species was not observed in platelets from the iPLA 2 c-KO mouse ( Figure 5 ). As shown in Figure 5A On the other hand, all most all of phospholipid subclasses were decreased by collagen stimulation and there was little difference in collagen-induced phospholipid hydrolysis between WT and iPLA 2 c-KO platelets. As shown in Figure 5B , iPLA 2 c-deficient mouse platelets in a resting state showed a tendency to contain lower PG subclasses with C 36:3 , C 36:4 , C 38:4 ,and C 38:5 than did WT mouse platelets. These PG species were decreased in WT mouse platelets, but not in iPLA 2 c-deficient mouse platelets after ADP or collagen stimulation. By contrast, there was no significant difference in composition of the diacyl forms of PE, or in essentially all of the molecular species of PC between WT and iPLA 2 c-KO (Figure 6 ). These data suggest that iPLA 2 c mainly catalyzes the hydrolysis of plasmalogen PE and PG-bearing C 18:2 and C 20:4 in a resting state, or ADP-activated platelets, and that these released AA are metabolized to eicosanoids, including TXA 2 .
Impaired Hemostasis and Decreased Susceptibility to Thromboembolism in iPLA 2 c-deficient Mice
To delineate the role of iPLA 2 c in platelet hemostasis and thrombus formation in vivo, a tail-bleeding time assay and thromboembolism test were performed. We first found that bleeding times were significantly longer in iPLA 2 c-KO mice than in gender-matched WT mice ( Figure 7A) .
Next, WT and iPLA 2 c-KO mice were intravenously injected with a mixture of collagen and epinephrine, which causes lethal pulmonary thromboembolism. This mouse model is often used to assess ADP-induced platelet activation in vivo. In fact, this model had revealed that both P2Y 1 genetic deletion and antagonists increased resistance to thrombosis in vivo [30, 31] . As shown in Figure 7B , histological examination showed marked thrombus formation in the arterioles of the lung in WT mice. Alveolar hemorrhage was also observed in broad areas, frequently accompanying massive pulmonary thrombosis. In contrast, scarce evidence of such thrombus formation or alveolar hemorrhage was found in the lung from iPLA 2 c-KO mice ( Figure 7C ). Only 10% of WT mice survived, whereas 50% of iPLA 2 c-KO mice were still alive 60 min after the challenge ( Figure 7D ). TXB 2 levels in the serum from iPLA 2 c-KO mice after injection were significantly lower than those from WT mice ( Figure 7E ). These results suggest that iPLA 2 c plays an important role in in vivo TXA 2 production accompanied by thrombus formation.
Discussion
PLA 2 plays a central role in platelet activation by hydrolysis of membrane phospholipids in response to a variety of stimuli. Previous studies have shown that, among several different PLA 2 enzymes, cPLA 2 a is critical for platelet activation, even though other PLA 2 (s) may also be involved [10] . The present study has revealed that iPLA 2 c, one of the Ca 2+ -independent intracellular PLA 2 enzymes, represents the missing link; it is also responsible for stimulus-dependent AA release and functions as a key enzyme in platelet aggregation in vitro and thrombus formation in vivo. Only the metabolic roles of iPLA 2 c have thus far been highlighted in vivo [23, 27, 32] . This is the first demonstration that iPLA 2 c has a previously unrecognized homeostatic role in a particular lineage of hematopoietic cells, namely platelets.
When WT platelets were stimulated with ADP, breakdown of PE (plasmalogen-type) and PG-bearing AA at the sn-2 position was obvious (Figures 5) . In sharp contrast, the amounts of these PE subclasses were unaffected by ADP stimulation in iPLA 2 c-deficient platelets. In addition to the release of AA, the production of TXA 2 was also reduced by iPLA 2 c deficiency (Figure 4) . These results suggest that in mouse platelets, iPLA 2 c is activated in ADPstimulated platelets and selectively hydrolyzes AA-containing plasmalogen-PE to release AA, leading to the production of TXA 2 . The production of other AA metabolites, such as 12(S)-HETE, PGE 2 and PGD 2 also tended to be reduced in iPLA 2 c-KO mouse platelets. iPLA 2 c might be preferentially coupled with COX-1-TXA 2 synthase pathway but a portion of iPLA 2 cliberated AA might be utilized by the other metabolic pathway. By comparison, in cPLA 2 a-deficient platelets, ADP-induced TXA 2 generation remained entirely intact and collagen-induced TXA 2 generation was reduced by only half [10] . This implies that, at least under these particular stimuli, iPLA 2 c could account largely, if still not solely, for the TXA 2 pool produced independently of cPLA 2 a. It should be noted that the levels of several PG subclasses tended to be lower in iPLA 2 c-deficient platelets than in WT platelets, even in the absence of stimuli ( Figure 5A ). The lower levels of these PG subclasses might lead to reduction in hydrolysis of PG in response to collagen, as well as to ADP. Cardiolipin and its precursor PG are mostly confined to mitochondrial membranes. Levels of both cardiolipin and PG were reduced in the heart, brain and skeletal muscle of the iPLA 2 c-deficient mice [23, 29, 32] . iPLA 2 c has been reported to be localized in the mitochondria, peroxisomes and ER of several cells [20, 27] . In mouse platelets, iPLA 2 c may be involved in the maintenance of mitochondrial membranes through membrane remodeling, as well as stimulus-dependent hydrolysis of phospholipids. However, mitochondrial morphology and activity (as monitored by ATP synthesis) appeared to be intact in iPLA 2 cdeficient platelets, underscoring a difference from the profound effects of iPLA 2 c deficiency on mitochondrial homeostasis in brain, heart and skeletal muscle [22, 29, 32] .
Selective hydrolysis of plasmalogen-type phospholipids in response to thrombin, collagen or U46619 has also been reported in human platelets [12] . Human platelets express both iPLA 2 b and iPLA 2 c; in that they differ from mouse platelets, in which iPLA 2 c is dominant. Amounts of arachidonylated plasmenylcholine and plasmalogen species were significantly decreased by thrombin stimulation in human platelets. It was also shown that pretreatment with the iPLA 2 c-specific inhibitor R-BEL inhibited these thrombin-stimulated phospholipid hydrolyses more effectively than iPLA 2 b inhibitor S-BEL [12] . Our previous experiments found that overexpression of iPLA 2 c caused reduction in AAcontaining plasmalogen subclasses in HEK293 cells [20] . Thus, activated iPLA 2 c appears to selectively hydrolyze AA-containing plasmalogen-type phospholipids not only in mouse platelets but also in several tissues and cells including human platelets. In mouse platelets, ADP-or collagen-induced TXA 2 generation was reduced by iPLA 2 c deficiency, although its generation in response to other stimuli such as thrombin was unaffected (Figure 4) . There was no difference in hydrolysis of plasmalogen PE in response to collagen between WT and iPLA 2 c-deficient platelets ( Figure 5B ). Agonist-dependent activation mechanism of iPLA 2 c might be different between human and mouse platelets.
Furthermore, in this study we found that among the agonists tested, only ADP-induced platelet aggregation was reduced by iPLA 2 c deficiency (Figure 2 ). Although TXA 2 generation induced by ADP or collagen was reduced (Figure 4) , aggregation in response to stimuli other than ADP, including collagen, was not affected. It has been reported that there are TXA 2 -dependent and -independent pathways in platelet aggregation [33, 34] . As iPLA 2 cdeficient platelets could fully aggregate in response to AA and U46619 (Figure 2 ), the TXA 2 -dependent aggregation pathway was not affected by iPLA 2 c deficiency. Our experiments using the P2Y 1 agonist and antagonist showed that iPLA 2 c is involved in P2Y 1 -mediated platelet aggregation ( Figure 3D and E). Although P2Y 1 is coupled with G q and its activation leads to Ca 2+ mobilization [29] , iPLA 2 c deficiency did not affect ADP-induced increment in intracellular Ca 2+ levels through G q -coupled P2Y 1 receptor ( Figure 3G ) Intraplatelet crosstalk between iPLA 2 c activation and Ca 2+ mobilization may regulate ADP-induced aggregation.
It is noteworthy that mice lacking iPLA 2 c have prolonged bleeding times and are resistant to thromboembolism induced by injection of epinephrine and collagen, as is the case with cPLA 2 adeficient mice [10] . These results indicate that iPLA 2 c plays a critical role in platelet hemostasis and thrombus formation in vivo, although iPLA 2 c deletion did not affect in vitro platelet aggregation in response to platelet activators other than ADP. As inappropriate thrombus formation could lead to acute coronary syndromes and progression of atherosclerotic disease, antithrombotic drugs are used for prevention and therapy for these diseases. Three classes of inhibitors of platelet aggregation have demonstrated substantial clinical benefits. Aspirin acts by irreversibly inhibiting COX-1, and therefore blocking the synthesis of TXA 2 . The indirect-acting (ticlopidine, clopidogrel, prasugrel) and directacting (ticagrelor) antagonists of P2Y 12 block the thrombusstabilizing activity of ADP. Parenteral GPIIb/IIIa inhibitors directly block platelet-platelet interactions. Despite well-established benefits, all of these antiplatelet agents have important limitations. iPLA 2 c has proven to be a potential target for antithrombotic drug development.
